PharmaJet Named Asia’s Most Innovative Vaccine Delivery System at the Vaccine World Asia Congress 2021

Needle-free technology continues to demonstrate innovation, growth, and positive impact

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet^®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.

The Asia Pacific Vaccine Excellence Awards 2021, organized by IMAPAC, celebrate the outstanding achievements of biopharmaceutical organizations, supply chain experts, and the newest innovations supporting the development and distribution of vaccines. The winners were announced at an awards ceremony that was part of the 3^rd Annual Vaccine World Asia Congress 2021 Conference held November 17-18. The Congress attracted over 800 representatives from Asia’s top vaccine and supply chain organizations.

Accepting the award Mr. LaBarre commented, “I am honored to receive this award on behalf of the PharmaJet team who come to work every day with a single mission: To improve people’s lives through our needle-free delivery technology. Working closely with our over 50 pharmaceutical partners, the World Health Organization, Bill and Melinda Gates Foundation, PATH and other NGOs, PharmaJet is the first and only needle-free system to receive WHO-prequalification, CE certification and FDA approved status. We have delivered millions of doses for polio immunization campaigns in Pakistan, Somalia, The Gambia and numerous other countries, while building a portfolio of positive clinical evidence for both therapeutics for cancer treatment and relevant vaccines such as Flu, HPV, Dengue, and Zika.” Underscoring PharmaJet’s most recent expansion, he further commented, “Well before mRNA and DNA vaccines were headline news, we foresaw the clear trends in our collaborator data indicating that the cellular dispersion, unique to needle-free delivery, resulted in improved nucleic acid vaccine immunogenicity when compared with needle and syringe delivery. In August of this year, we saw the power of these collaborations realized at scale, with the EUA of Zydus Cadila's ZyCov-D, the first commercialized plasmid-DNA vaccine, the first vaccine delivered exclusively needle-free. With many of our collaborators advancing quickly to advanced clinical studies and commercialization, we foresee a rapid adoption of needle-free delivery across the world.”

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

About PharmaJet
PharmaJet’s mission is to improve people’s lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis^® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.